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Abstract
Analyses of randomised trials are often based on regression models which adjust for baseline covari-
ates, in addition to randomised group. Based on such models, one can obtain estimates of the marginal
mean outcome for the population under assignment to each treatment, by averaging the model based
predictions across the empirical distribution of the baseline covariates in the trial. We identify under
what conditions such estimates are consistent, and in particular show that for canonical generalised lin-
ear models, the resulting estimates are always consistent. We show that a recently proposed variance
estimator underestimates the true variance when the baseline covariates are not fixed in repeated sam-
pling, and provide a simple adjustment to remedy this. We also describe an alternative semiparametric
estimator which is consistent even when the outcome regression model used is misspecified. The different
estimators are compared through simulations and application to a recently conducted trial in asthma.
1 Introduction
Analyses of randomised clinical trials often adjust for one or more baseline covariates, typically through
fitting a regression model for the outcome variable, conditional on randomised group and the specified
baseline covariates. The purposes of such adjustment is usually primarily to take account of chance
imbalance in the distribution of the baseline covariates between treatment groups. Statistically such
adjustment generally improves the power of a test of the null hypothesis of no treatment effect. For linear
outcome models the estimated treatment effect is also more precise, while for non-linear outcome models
the situation is more nuanced, since in general covariate adjustment alters the conditional treatment
effect being targeted [15].
In addition to reporting baseline covariate adjusted estimates of treatment effect, trial reports almost
always report crude or raw summary statistics such as means for the outcome, by treatment group.
Since the primary treatment effect estimate is adjusted for baseline covariates, a natural although less
common next step is to report estimates or predictions of mean outcome by treatment group which take
the baseline covariates into account.
As described recently by Qu and Luo [10], some statistical packages provide estimates by calculating
predictions for the mean outcome for a given treatment, setting the baseline covariates to their mean
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values in the sample ‘prediction at the mean’. An alternative, also described by [10], involves predicting
the mean outcome assuming assignment to a particular treatment for each patient in the trial, using each
patient’s observed baseline covariates, and averaging these predictions across all patients in the trial. We
refer to this as the ‘marginal mean’ method. For linear models, the two approaches give identical results,
while for non-linear models, such as logistic or Poisson regression, in general they do not [7]. Indeed, for
non-linear models, the population parameters being estimated by the two approaches differ.
The marginal mean approach predicts what the mean outcome would be if the population were
assigned a given treatment. This is the same population parameter estimated by the crude treatment
group specific mean outcome. In contrast, ‘prediction at the mean’ predicts the mean outcome for a
patient with baseline covariate values equal to their means. As noted by others [8], when some of the
covariates are categorical, such as gender or region, ‘prediction at the mean’, or prediction with other
proportions assigned to the levels of categorical variables, arguably makes little sense. This is because
any given patient can only belong to one level of each categorical covariate, and the resulting predicted
value applies to a patient with covariate values that are never and can never be seen in the population.
Qu and Luo recently proposed using the marginal mean approach in randomised trials to estimate
treatment group specific means, and advocated its use in preference over ‘prediction at the mean’ for
non-linear outcome models [10]. In addition to point estimation, Qu and Luo described a variance
estimator for the marginal mean estimates, and demonstrated that the resulting estimator was unbiased
and confidence intervals achieved their nominal coverage level.
In this paper we investigate marginal mean estimation in further detail. In Section 2 we review crude
marginal mean estimation in trials, whereby baseline covariates are not utilised. In Section 3 we consider
the estimator described by Qu and Luo in detail. We first describe conditions under which it is consistent,
and show that for certain outcome model types it remains consistent even when the outcome regression
model is misspecified. We then show that when, as is typically the case, baseline covariates would not
be fixed in repeated samples, the variance estimator described by Qu and Luo underestimates the true
sampling variance, and we give a simple adjustment which remedies this. In Section 4 we consider an
alternative semiparamtric baseline adjusted estimator which is guaranteed to be unbiased irrespective of
whether the outcome model is correctly specified. Next in Section 5 we consider the impact of stratified
randomisation on the preceding results. In Section 6 we report simulation results comparing the different
estimators. As an illustrative example in Section 7 we present results from a recently conducted trial in
asthma. We conclude with a discussion in Section 8.
2 Marginal mean estimation ignoring covariates
Consider a randomised trial where Z is a variable recording the an individual patient’s randomised
treatment group. Let Y denote the patient’s outcome on their assigned treatment. Let Y z denote the
potential outcome for an individual patient were they, possibly contrary to fact, given treatment z [5].
The (true) marginal mean outcome under treatment z is then defined as
µ(z) = E(Y z) (1)
Randomisation ensures that µ(z) = E(Y z) = E(Y |Z = z), so that µ(z) can be estimated by the sample
mean outcome in those patients randomised to Z = z:
µˆ1(z) =
∑n
i=1 1(Zi = z)Yi∑n
i=1 1(Zi = z)
2
where 1() denotes the indicator function which takes value one when its argument is true, and takes value
zero otherwise. The mean for each treatment group is calculated and reported as a matter of course in
randomised trials. Provided the trial used simple randomisation, the variance of µˆ1(z) can be estimated
in the usual way for the variance of a sample mean of independent random variables.
In trials where the outcome Y represents the number of events that occur in each patient during
follow-up, the length of follow-up sometimes varies between patients (for various reasons). Let T denote
an individual patient’s follow-up time. In this case, one typically assumes that E(Y |T, Z = z) = µ(z)T ,
and interest lies in estimation of the event rate µ(z). In this case µ(z) is estimated by the sample rate
µˆ1(z) =
∑n
i=1 1(Zi = z)Yi∑n
i=1 1(Zi = z)Ti
(2)
A sandwich variance estimator for the latter estimator, derived later in Section 4, is given by
τˆ
−2
z n
−2
z
n∑
i=1
[1(Zi = z){Yi − µˆ1(z)}]
2 (3)
where nz denotes the number of patients randomised to Z = z and τˆz denotes the mean follow-up time
in those randomised to Z = z.
3 Baseline adjusted marginal mean estimation
As described in the introduction, trials almost always collect baseline covariates X which are related, to
a greater or lesser extent, to the outcome Y . In this section we consider estimation of µ(z) where we
utilise such covariates in the estimation of µ(z).
3.1 Outcome model specification and estimation
We assume that the trial’s analysis plan specifies a regression model for Y with X and Z as covariates.
This could be a fully parametric model, or a semiparametric model, but we require that it at least
specifies how the mean of Y depends on X and Z:
E(Y |X,Z) = h(X,Z, β) (4)
for an assumed function h(X,Z, β) and where β are the model parameters. The most common specifi-
cation is that
h(X,Z, β) = g−1(β0 + β
T
XX + βZZ)
for some link function g(). In the case of more than two treatment groups, Z would be replaced in the
linear predictor by a vector of indicator functions. The outcome model may sometimes contain additional
parameters η, such as the residual variance in the case of linear regression or the dispersion parameter in
the case of a negative binomial regression. In the case where patients are followed up for different lengths
of time, one assumes E(Y |X,Z, T ) = Th(X,Z, β). In statistical software this assumption is specified by
passing the patient’s follow-up time as an appropriate offset.
We let βˆ denote the estimated value of β. In cases where the outcome model is fully parametric, the
parameters are usually estimated by maximum likelihood. More generally, we assume that β is estimated
as the value solving a set of estimating equations, which are consistent for the true value of β when the
outcome model is correctly specified. We let β˜ denote the large sample probability limit of the estimator
βˆ. This is the value that is consistently estimated as the sample size n tends to infinity.
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3.2 Estimation of µ(z)
To estimate µ(z) using the baseline adjusted outcome model, we can use the law of total expectation to
express
µ(z) = E(Y z) = E{E(Y z|X)} (5)
This expression says that µ(z) can be calculated by predicting the mean outcome under treatment z for
each patient given their baseline covariates X, and then averaging these predictions across all patients.
This motivates the estimator described by Qu and Luo [10], which is given by:
µˆ2(z) = n
−1
n∑
i=1
h(Xi, z, βˆ) (6)
We emphasise that this estimator, unlike µˆ1(z), uses data from all patients, and not only those randomised
to Z = z. It is an example of a standardisation estimator, where we are standardising to the empirical
distribution of the baseline covariates of all patients in the trial [5].
3.3 Consistency
Since µˆ2(z) is the sample mean of h(X, z, βˆ), it follows that µˆ2(z) is a consistent estimator of E{h(X, z, β˜)}.
It will therefore be consistent if and only if E{h(X, z, β˜)} = µ(z). A sufficient condition for this to hold
is that E(Y |X,Z) = h(X,Z, β˜). This is satisfied in particular if the outcome model is correctly specified.
In general, if the outcome model is misspecified, µˆ2(z) is biased for µ(z).
There are however important cases where E(Y |X,Z) = h(X,Z, β˜) even when the outcome model is
misspecified in certain respects. Specifically, when the outcome model is a generalised linear model, it is
sufficient that the conditional mean E(Y |X,Z) = h(X,Z, β) is correctly specified. For example, if the
outcome model is Poisson regression, provided the conditional mean specification is correct, there is no
need for Y to be Poisson distributed conditional on X and Z. A similar argument applies in the case of
negative binomial regression (NB2), whereby the regression parameters are estimated (asymptotically)
without bias provided the conditional mean function is correctly specified [4].
Moreover, in the special case of canonical generalised linear models (GLM), we show in Appendix
A.1 that µˆ2(z) remains consistent even if the conditional mean model is misspecified. This robustness
property for canonical GLMs in randomised trials was previously derived within the framework of targeted
maximum likelihood by Rosenblum and van der Laan [11].
Consider again the setting where the outcome Y represents the number of events that occur for each
patient during follow-up, with T denoting a patient’s follow-up time. Suppose that Poission regression is
used for the outcome model, with log(T ) as an offset. In Appendix A.1, we show that provided T ⊥⊥ X|Z,
µˆ2(z) is consistent for µ(z) irrespective of whether the Poisson regression is correctly specified.
3.4 Variance
We now consider the variance of µˆ2(z), and estimators of this variance. Qu and Luo [10] proposed a
variance estimator for µˆ2(z) using the delta method, in which they conditioned on the observed covariate
values X = {Xi, i = 1, .., n}, Z = {Zi, i = 1, .., n}. The marginal mean estimator given by equation (6) is
a non-linear transformation of βˆ, and so by the delta method its (conditional) variance can be estimated
by
V̂ar(µˆ2(z)|X,Z) = GˆβV̂ar(βˆ|X,Z)Gˆ
T
β (7)
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where
Gˆβ = n
−1
n∑
i=1
∂h(Xi, z, βˆ)
∂βT
(8)
For V̂ar(βˆ|X,Z), one could use the model based variance covariance matrix, or as Qu and Luo also
described, a robust sandwich variance estimator [10].
Qu and Luo’s variance estimator for µˆ(z) treats the covariate values in the sample as fixed known
constants. This is in agreement with conventional inference methods for regression models parameters,
which also treat the observed covariate values as fixed. In the vast majority of late phase randomised
trials, the individual covariate values are not fixed, in the sense that if the sample or trial were to be
repeated, the covariate values which would be observed would change.
Although not often made explicit, for inference regarding parameters of regression models, the practice
of treating covariates as treated as fixed even when in truth they are not can be justified through the
concept of ancilliarity. Specifically, in the regression setting, the marginal distribution of the covariates
is ancilliary, which means inference for parameters of the conditional distribution of the outcome given
the covariates can be performed as if the covariates were in fact fixed [3].
This argument does not apply however to µˆ2(z), since it depends not only on the regression coefficients
of the outcome model but also on the marginal distribution of the baseline covariates X. In Appendix
A.2, we use estimating equation theory to derive an expression for the repeated sampling variance of µˆ2(z)
which accounts for X being randomly sampled, and which shows that the variance estimator described
by Qu and Luo is in general invalid when X are not fixed in repeated sampling. In Appendix A.2 we
show that when the outcome model is correctly specified, or is a GLM or negative binomial regression
with the conditional mean function correctly specified, the Qu and Luo variance estimator is downwardly
biased by
n
−1Var
[
h(X, z, β˜)− µ(z)
]
The downward bias can thus be remedied by adding
n
−2
n∑
i=1
{h(X, z, βˆ)− µˆ2(z)}
2 (9)
to the Qu and Luo variance estimator given in equation (7). The form of this expression shows that the
Qu and Luo variance estimator may be expected to be downwardly biased to a greater extent when the
baseline covariates X are strongly associated with Y . Conversely, we expect the Qu and Luo variance
estimator to be approximately unbiased for the variance of µˆ2(z) when the baseline covariates are only
weakly associatied with outcome.
The covarate adjusted estimator µˆ2(z) takes into account the effects on the outcome mean of any
chance imbalances in the distribution of the baseline covariates X between treatment groups. One might
therefore expect µˆ2(z) to give a more precise estimate of µ(z) than the unadjusted estimator µˆ1(z). In
Appendix A.3 we give a sketch proof that shows that when the outcome model is a correctly specified
parametric model, µˆ2(z) is indeed more efficient than µˆ1(z).
4 Robust baseline adjusted marginal mean estimation
As described previously, the estimator µˆ2(z) can give a more precise estimate of µ(z) than µˆ1(z), by
exploiting the baseline covariates and the randomisation assumption. However, it is only consistent for
µ(z) in general when the outcome model used is correctly specified. In contrast, the crude mean estimator
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µˆ1(z) which does not use the baseline covariates, is (assuming there is no missing data) always unbiased.
As we describe in Appendix B.1, using the semiparametric theory developed by Tsiatis [14] and Zhang
et al [17], we can construct an estimator µˆ3(z) that exploits X to improve efficiency, yet like µˆ1(z) is
guaranteed to be consistent. This estimator is given by
µˆ3(z) = µˆ1(z)− n
−1
n∑
i=1
[
1(Zi = z)− pˆiz
pˆiz
h(Xi, z, βˆ)
]
(10)
where pˆiz denotes the sample proportion of patients randomised to Z = z and h(X,Z, βˆ) denotes a
working model prediction for E(Y |X,Z). This estimator remains consistent even if the working model
E(Y |X,Z) = h(X,Z, β) is misspecified, since the second term in the expression has mean zero due
to independence of X and Z. However misspecification will affect the estimator’s variance, with the
variance being minimized when the working model is correctly specified. In Appendix B.1 we show that
the variance of µˆ3(z) can be estimated by
pˆi
−2
z n
−2
n∑
i=1
[
1(Zi = z){Yi − µˆ3(z)} − {1(Zi = z)− pˆiz}{h(Xi, z, βˆ)− µˆ2(z)}
]2
(11)
This approach can be used for estimation of µ(z) for each treatment group. A separate model for
E(Y |X,Z = z) for each z could be fitted to those randomised to Z = z, or alternatively, a single
regression model could be fitted to all treatment groups, and the model fit used to construct estimates
of E(Y |X,Z = z) for each value of z. Note that if one chooses h(X,Z, β) = 0, µˆ3(z) reduces to µˆ1(z),
and as such, equation (11) can also be used to obtain a robust sandwich variance estimator for µˆ1(z) by
ignoring the second term in square brackets (since if h(X,Z, β) = 0, µˆ2(z) = 0).
In the case where Y denotes the number of events observed on a patient and T denotes their follow-
up time, in Appendix B.1 show that µˆ1(z) remains as per equation (10), with h(X, z, β) denoting the
working model prediction for E(Y |X,Z, T = 1). We also show that its variance can be estimated by
pˆi
−2
z τˆ
−2
z n
−2
n∑
i=1
[
1(Zi = z){Yi − µˆ3(z)} − τˆz{1(Zi = z)− pˆiz}{h(Xi, z, βˆ)− µˆ2(z)}
]2
(12)
where τˆz denotes the mean follow-up time in those randomised to Z = z.
In Section 3 we described how µˆ2(z) is consistent irrespective of whether the outcome model is
correctly specified in the special case that the latter is a canonical generalised linear model. This result
can also be demonstrated in this special case by showing that µˆ2(z) = µˆ3(z), and hence µˆ2(z) inherits
the robustness property of µˆ3(z).
5 Stratified randomisation
Thus far we have assumed that each patient’s treatment group is assigned using simple randomisation,
such that the data on each patient is independent and identically distributed. In practice, alternative
randomisation schemes are often used. The most common is stratified randomisation. It is well known
that such schemes introduce a dependence in the data, which if ignored, leads to conservative inferences
for treatment effect estimates [13, 6, 2]. In particular, although stratified randomisation will not affect
consistency of the estimators, it will affect their variance. In the following, we consider how stratified
randomisation impacts on µˆ1(z), µˆ2(z), and µˆ3(z).
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5.1 µˆ1(z)
Stratified randomisation ensures that for the covariates used in the randomisation, their sample distri-
bution is identical or near identical across treatment groups. This means that the distribution of these
covariates in those randomised to Z = z is, in expectation, closer to the population distribution than
would be expected under simple randomisation. As such, we would expect the usual i.i.d. variance
estimator for µˆ1(z) to be biased upwards when stratified randomisation is used. We investigate this
conjecture in the simulation study described in Section 6.
5.2 µˆ2(z)
We first consider µˆ2(z) when the covariates adjusted for include all of those used in the stratified ran-
domisation. The theory developed previously for the variance of µˆ2(z) assumed that patients’ data are
i.i.d. In Appendix C we show that provided the outcome model is correctly specified, the variance of
µˆ2(z) can be estimated as described previously in the case of simple randomisation.
Now suppose that the covariates X adjusted for are exactly those used in the stratified randomisation,
i.e. that the outcome model does not adjust for any additional covariates not used in the stratified
randomisation. As noted previously, under stratified randomisation, the sample distribution of X is
identical, or near identical, across the treatment groups. As such, we might expect that µˆ2(z) would
not have improved efficiency compared to µˆ1(z), since those randomised to treatments other than z give
no additional information about the population distribution of X. To demonstrate this conjecture in a
special case, suppose that there exists a single binary baseline covariate X, randomisation was performed
stratified on X, and that there are two treatment groups. Suppose we fit a canonical GLM for the
outcome conditional on Y and X and Z, with main effects of X and Z. The outcome model estimating
equations then consist of
n∑
i=1
{Yi − h(Xi, Zi, βˆ)}
 1Xi
Zi
 = 0
A consequence is that
∑
ZiYi =
∑
Zih(Xi, 1, βˆ). Since the sample distribution of X is identical (or
almost identical) across treatment groups as a consequence of stratified randomisation,∑n
i=1 Zih(Xi, 1, βˆ)∑n
i=1 Zi
≈
∑n
i=1(1− Zi)h(Xi, 1, βˆ)∑n
i=1(1− Zi)
so that
µˆ2(1) = n
−1
n∑
i=1
h(Xi, 1, βˆ)
≈
∑n
i=1 Zih(Xi, 1, βˆ)∑n
i=1 Zi
=
∑n
i=1 ZiYi∑n
i=1 Zi
= µˆ1(1)
A similar argument naturally carries through for z = 0. Thus the estimators µˆ1(z) and µˆ2(z) are
essentially equivalent, and there is no gain in precision over µˆ1(z).
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5.3 µˆ3(z)
In general, the variance estimator described assuming data are i.i.d. for µˆ3(z) is not expected to be valid
under stratified randomisation. This can be seen by the fact that µˆ3(z) reduces to µˆ1(z) upon choosing
h(X,Z, β) = 0, and as described previously, we expect the i.i.d. variance estimator for µˆ1(z) to be biased
upwards under stratified randomisation.
6 Simulations
In this section we present simulation results to investigate the finite sample properties of the methods
described, first where random permuted block randomisation is used, and second where stratified ran-
domisation is used. Treatment allocation was performed with P (Z = 1) = 0.5. We simulated data for
trials of size n = 400, with a single binary covariate X ∼ Bernoulli(0.5). For a random 25% of patients
their follow-up time T was generated from a uniform distribution on (0, 1), with the remainder having
follow-up T = 1. We investigated the estimators described previously in four different scenarios:
1. Yi generated from a Poisson distribution, with mean γiTi exp(3Xi + Zi), where γi was gamma
distributed with shape 2 and scale 1/2. The working model used for µˆ2(z) and µˆ3(z) was a negative
binomial model, with main effects of Xi and Zi, and log(Ti) as offset
2. Yi generated in the same way, but with γi a log normally distributed random effect with mean
1 and variance 1/2. The working model used for µˆ2(z) and µˆ3(z) was again a negative binomial
model with main effects of Xi and Zi, and log(Ti) as offset
3. Yi generated from a Poisson distribution, with mean γiTi exp(3Xi + Zi − 1.5XiZi), where γi was
gamma distributed with shape 2 and scale 1/2. The working model used for µˆ2(z) and µˆ3(z) was
again a negative binomial model with main effects of Xi and Zi, and log(Ti) as offset
4. Yi generated from a Poisson distribution, with mean γiTi exp(3Xi + Zi − 1.5XiZi), where γi was
gamma distributed with shape 2 and scale 1/2. The working model used for µˆ2(z) and µˆ3(z) was
a Poisson model with main effects of Xi and Zi, and log(Ti) as offset
We note that these scenarios assume very strong associations between X and the outcome, since it is
the strength of this association that largely drives the differences we expect to see. The variance of
µˆ1(z) was estimated using equation (3). The Qu and Luo variance estimator for µˆ2(z) was calculated
using equation (7), with a sandwich variance estimator used to estimate the variance of βˆ. The term
in equation (9) was then added to this variance to allow for the fact that X was not fixed in repeated
samples. The variance of µˆ3(z) was calculated using equation (12). Confidence intervals were calculated
on the log scale and then back transformed.
Table 1 shows the results of the simulations with random permuted block randomisation. As expected,
µˆ2(1) was unbiased when the outcome regression model was correctly specified (scenario 1). It was also
unbiased when the random effects distribution was modelled incorrectly (scenario 2), since as described
earlier, with full data, the negative binomial model gives consistent estimates of the regression coefficients
provided the conditional mean function is correctly specified. In scenario 3, the conditional mean function
in the outcome model was misspecified, and so µˆ2(1) was biased. In scenario 4 µˆ2(1) was unbiased, despite
the conditional mean function being misspecified, since a canonical GLM (Poisson) model was used. As
expected, µˆ2(1) was more efficient than µˆ1(1). Confidence intervals based on the fixed X standard error
described by Qu and Luo [10] had coverage below the nominal 95% level, as predicted by theory. In
contrast, in those scenarios where µˆ2(1) was unbiased, the coverage of the random X confidence intervals
was close to the 95% level. This was the case even in scenario 4, using a misspecifed Poisson model, a
result which does not appear to be implied theoretically. The robust estimator µˆ3(1) was unbiased in all
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four scenarios, was more efficient than µˆ1(1), and confidence intervals had coverage just sllightly below
the 95% level.
Table 1: Bias and coverage of 95% confidence intervals for µˆ1(1), µˆ2(1), µˆ3(1), across 10,000 simulations.
Rel. eff. denotes the ratio of the empirical variance of µˆ1(1) to the variance of µˆ2(1) or µˆ3(1).
Scenario 1 Scenario 2 Scenario 3 Scenario 4
µˆ1(1)
Mean 3.88 3.88 2.80 2.81
95% CI Cov. 94.53 94.28 94.69 94.61
µˆ2(1)
Bias 0.00 0.00 0.18 0.00
Rel. eff. 1.28 1.28 1.14 1.22
Fixed X 95% CI Cov. 89.61 89.20 81.96 91.15
Random X 95% CI Cov. 94.41 94.20 88.87 95.08
µˆ3(1)
Bias 0.00 0.00 0.00 0.00
Rel. eff. 1.26 1.25 1.21 1.22
95% CI Cov. 94.47 94.30 94.67 94.56
Table 2 shows the results of simulations where randomisation was stratified on X. As conjectured,
the i.i.d. confidence intervals for µˆ1(1) had coverage higher than 95%. Also, since the covariate X was
stratified on in the randomisation, neither µˆ2(1) nor µˆ3(1) had improved efficiency relative to µˆ1(1).
Fixed X confidence intervals for µˆ2(1) again under covered, whereas the random X intervals had correct
coverage whenever µˆ2(1) was unbiased. Interestingly, confidence intervals for µˆ3(1) had correct coverage,
even in scenario 3 where the working conditional mean model was misspecified. Further research is
warranted to understand the reason for this.
Table 2: Bias and coverage of 95% confidence intervals for µˆ1(1), µˆ2(1), µˆ3(1), across 10,000 simulations,
with stratified randomisation. Rel. eff. denotes the ratio of the empirical variance of µˆ1(1) to the variance
of µˆ2(1) or µˆ3(1).
Scenario 1 Scenario 2 Scenario 3 Scenario 4
µˆ1(1)
Mean 3.88 3.88 2.81 2.81
95% CI Cov. 96.84 96.83 96.70 96.88
µˆ2(1)
Bias 0.00 0.00 0.18 0.00
Rel. eff. 1.02 1.02 0.94 1.00
Fixed X 95% CI Cov. 89.52 89.44 82.28 91.88
Random X 95% CI Cov. 94.19 94.39 88.65 95.21
µˆ3(1)
Bias µˆ3(1) 0.00 0.00 0.00 0.00
Rel. eff. 1.00 1.00 1.00 1.00
95% CI Cov. 94.05 94.27 94.78 94.90
7 Illustrative analysis
In this section we re-analyse data from the Sirocco trial, a randomised placebo controlled phase 3 trial
designed to investigate the efficacy and safety of benralizumab in patients with severe asthma [1]. Across
374 sites in 17 countries, 1,205 patients were randomised. Randomisation was stratified by age group,
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country/region, and blood eosinophil count category. The primary analysis population consisted of those
patients with blood eosinophil counts at least 300 cells per L, in which 267 were randomised to placebo,
275 to benralizumab 30 mg every 4 weeks, and 267 to benralizumab 30 mg every 8 weeks. The analyses
presented here are based on a de-identified version of the data with patients who revoked their informed
consent removed, and which includes 257 patients on placebo, 263 patients on benra 4 week, and 256
patients on benra 8 week.
The primary outcome was asthma exacerbations during a planned 48 week follow-up period. In the
subset used here, approximately 95% of patients had at least 46 of the planned 48 weeks of follow-up. The
primary outcome was analysed using negative binomial regression, with randomised treatment group,
region, exacerbations in the previous year (two, three, or four or more), and oral corticosteroid use at
time of randomisation. As part of the trial’s results [1], µˆ2(z) was calculated using the negative binomial
model for each of the three treatment groups, with 95% CIs calculated using the method proposed by
[10].
Table 3 shows the estimated asthma exacerbation rates using µˆ1(z), µˆ2(z) and µˆ3(z) for each of
the three treatment groups. For µˆ2(z) and µˆ3(z) estimates are shown both for a negative binomial
and Poisson model, in which the same covariates were adjusted for as in the trial’s primary analysis.
Confidence intervals are shown based on the method proposed by Qu and Luo [10], treating the baseline
covariates as fixed, and using the adjustment given in equation (9). Sandwich variances were used to
estimate the variance covariance matrix of the models’ regression parameters.
For the rate under placebo the covariate adjusted estimates are all smaller than the crude rate. For
benra 4 weeks the crude and adjusted estimates are quite similar, while for benra 8 weeks the covariate
adjusted estimates are all somewhat higher than the crude rate. Differences between the crude and
adjusted estimates are to be expected since as described previously, the latter adjust the crude rates for
chance imbalance in the baseline covariate distribution between randomised groups. Differences between
the various covariate adjusted estimates for each treatment were small.
The confidence intervals for µˆ2(z) constructed as proposed by Qu and Luo [10] were very slightly
narrower than those that include the adjustment given in equation (9). Thus here assuming the covari-
ates were fixed for the purposes of variance estimation of µˆ2(z) made very little difference. This can
be explained by the fact that although some of the baseline covariates adjusted for were statistically
significant with moderately large associations, their estimated associations were nevertheless smaller in
magnitude than what was assumed in the simulation study.
Table 3: Estimates of asthma exacerbation rate from the Sirocco trial with 95% confidence intervals. NB
- negative binomial. ‘Fixed X’ and ‘Random X’ correspond to confidence intervals calculated assuming the
covariates are fixed or random respectively.
Placebo Benra 4 weeks Benra 8 weeks
µˆ1 1.536 (1.287, 1.833) 0.836 (0.667, 1.049) 0.652 (0.523, 0.813)
µˆ2 NB Fixed X 1.464 (1.245, 1.722) 0.819 (0.561, 1.195) 0.710 (0.456, 1.107)
µˆ2 NB Random X 1.464 (1.240, 1.729) 0.819 (0.560, 1.197) 0.710 (0.455, 1.109)
µˆ3 NB 1.483 (1.247, 1.764) 0.839 (0.662, 1.063) 0.676 (0.546, 0.836)
µˆ2 Poisson Fixed X 1.490 (1.268, 1.751) 0.841 (0.575, 1.228) 0.676 (0.413, 1.107)
µˆ2 Poisson Random X 1.490 (1.263, 1.758) 0.841 (0.574, 1.230) 0.676 (0.412, 1.108)
µˆ3 Poisson 1.482 (1.247, 1.762) 0.840 (0.662, 1.065) 0.674 (0.545, 0.834)
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8 Discussion
When a randomised trial’s analysis adjusts for baseline covariates, we believe it is advisable to also
estimate and report baseline adjusted estimates of mean outcome under each treatment. Estimating
the mean outcome when the baseline covariates are equal to their corresponding means arguably makes
little sense when some baseline covariates are categorical. Instead, the marginal mean estimator µˆ2(z)
proposed by Qu and Luo [10], targets the same parameter as the unadjusted group mean µˆ1(z), but
removes variation attributable to chance imbalance in the distribution of baseline covariates between
randomised groups. Assuming the outcome model used is correctly specified, this leads to mean estimates
with improved precision.
We have shown that the variance estimator for µˆ2(z) described by Qu and Luo [10] will in general
be biased downwards when, as is the case usually, patients’ baseline covariate values would not be fixed
in repeated sampling. This bias may however be small unless the covariate effects on outcome are large.
We have proposed a simple adjustment to the Qu and Luo variance estimator, which results in a valid
variance estimator provided the outcome model is correctly specified.
Semiparametric methods which adjust for baseline covariates offer the opportunity for tests of treat-
ment effect with improved power while remaining valid when the working model involved is incorrectly
specified [17]. As we have shown, this methodology leads directly also to estimates of µ(z), offering im-
proved precision relative to µˆ1(z), but unlike µˆ2(z), retaining consistency even when the working model
is misspecified.
As others have described previously, use of covariate adaptive randomisation schemes such as stratified
randomisation offers the potential for more precise inferences to be made. Nevertheless, this potential is
only realised when the analysis correctly accounts for the randomisation scheme. As we have described,
stratified randomisation causes naive i.i.d. variance estimates for µˆ1(z) to be upwardly biased. Further
research is warranted to understand under what conditions the i.i.d. variance estimator for µˆ3(z) remains
valid under covariate adaptive randomisation schemes.
We have throughout assumed that the baseline covariates and outcome are fully observed. While
the former are typically fully observed in randomised trials, the latter is often incomplete. When some
outcomes are missing in those randomised to Z = z, µˆ1(z) is only unbiased if missingness is independent
of outcome within each treatment group, an assumption which often is not plausible. When the outcome
model used is correctly specified, the adjusted estimator µˆ2(z) is however valid under the weaker as-
sumption that missingness is independent of outcome conditional on covariates. For µˆ3(z), unbiasedness
is only guaranteed in general when missingness is independent of outcome. We note that the methods
described here could of course be used in conjunction with multiple imputation or inverse probability
weighting for handling such missingness.
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A Asymptotic theory for µˆ2(z)
A.1 Consistency
Here we show that µˆ2(z) is consistent for certain outcome models, irrespective of whether the outcome
model is correctly specified. As noted in Section 3, µˆ2(z) is consistent if and only if E{h(X, z, β˜)} = µ(z).
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Suppose that the outcome model is a canonical generalised linear model. Then if there are k treatment
groups, the estimating equations for β are
n∑
i=1
{Yi − h(Xi, Zi, β)}

1
Xi
1(Zi = 1)
...
1(Zi = k)

= 0
and the large sample limits β˜ satisfies
E

{Y − h(X,Z, β˜)}

1
X
1(Z = 1)
...
1(Z = k)


= 0
This means in particular that
0 = E
[
1(Z = z){Y − h(X,Z, β˜)}
]
= piz
[
µ(z)− E{h(X, z, β˜)}
]
so that E{h(X, z, β˜)} = µ(z), and hence µˆ2(z) is consistent.
Now consider the setting where Y denotes the number of events occurring for a patient, and T denotes
their follow-up time. Suppose we use Poisson regression with the canonical log link, with log(T ) as an
offset. Then we have that
0 = E
[
1(Z = z){Y − Th(X,Z, β˜)}
]
Now suppose that T ⊥⊥ X|Z. Then
0 = pizE(T |Z = z)µ(z)− pizE(T |Z = z)E{h(X, z, β˜)}
so that E{h(X, z, β˜)} = µ(z), and hence µˆ2(z) is again consistent.
A.2 Variance
In this appendix we derive an expression for the sampling variance of µˆ2(z), assuming the baseline
covariates are random in repeated sampling. To find the asymptotic distribution of µˆ2(z) which accounts
for X being random, we use the estimating equation theory described by Newey and McFadden [9]. In
addition to the parameters β indexing the conditional mean function, the outcome model may contain
additional parameters η. We let θ = (β, η) denote the combined parameter. We assume that θ is
estimated by the value θˆ = (βˆ, ηˆ) solving a set of estimating equations
0 =
n∑
i=1
m(Yi, Xi, Zi, θˆ) (13)
for some estimating function m(Y,X,Z, θ). In the case where the outcome model is fitted by maximum
likelihood, the estimating equations correspond to the likelihood score equations. We let θ˜ = (β˜, η˜)
denote the large sample probability limit of the estimator.
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The estimator µˆ2(z) is a so called two step estimator. Suppose that E{h(X, z, β˜)} = µ(z), so that
µˆ2(z) is consistent. Application of Theorem 6.1 of Newey and McFadden [9] then states that, under
regularity conditions, µˆ2(z) is asymptotically normally distributed, with mean µ(z), and variance
n
−1Var
[
h(X, z, β˜)− µ(z) +Gθψ(Y,X,Z)
]
(14)
where ψ(Y,X,Z) is the so called influence function of θˆ, and
Gθ = E
[
∂
∂θT
{h(X, z, β˜)− µ(z)}
]
=
(
E
[
∂
∂βT
h(X, z, β˜)
]
0
)
=
(
Gβ 0
)
(15)
The influence function of θˆ is equal to
ψ(Yi, Xi, Zi) = −M
−1
m(Yi, Xi, Zi, θ˜)
where
M = E
[
∂
∂θT
m(Y,X,Z, θ˜)
]
In full generality, the variance of µˆ2(z) can be estimated by
V̂ar{µˆ2(z)} = n
−2
n∑
i=1
[
h(X, z, βˆ)− µˆ(z) + Gˆθψˆ(Y,X,Z)
]2
(16)
where
ψˆ(Y,X,Z) = −Mˆ−1m(Yi, Xi, Zi, θˆ),
Mˆ = n−1
n∑
i=1
∂
∂θT
m(Yi, Xi, Zi, θˆ),
and
Gˆθ =
(
n−1
∑n
i=1
∂h(Xi,z,θˆ)
∂θT
0
)
In certain situations, a simplification of the preceding variance estimator is possible. The variance in
equation (14) can be expanded as
Var
[
h(X, z, β˜)− µ(z) +Gθψ(Y,X,Z)
]
= Var
[
h(X, z, β˜)− µ(z)
]
+Var [Gθψ(Y,X,Z)]
+ 2Cov
[
h(X, z, β˜)− µ(z), Gθψ(Y,X,Z)
]
(17)
The covariance term can be expanded as
Cov
[
E{h(X, z, β˜)− µ(z)|X,Z}, E{Gθψ(Y,X,Z)|X,Z}
]
+E
[
Cov{h(X, z, β˜)− µ(z), Gθψ(Y,X, Z)|X,Z}
]
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The second term in this expression is zero, since the first component is constant, conditional on X and
Z. Now suppose that the outcome model estimating function is conditionally unbiased, in the sense that
E{m(Y,X,Z, θ˜)|X,Z} = 0 (18)
This condition typically holds if the outcome model is a correctly specified parametric regression model
estimated by maximum likelihood, where the estimating equation for θ is the likelihood score equa-
tion (see for example page 393 of [16]). It holds for generalised linear models provided the condi-
tional mean function is correctly specified. It is also satisfied when the outcome model is a correctly
specified semiparametric conditional mean model [12]. When the condition holds, it then follows that
E{Gθψ(Y,X,Z)|X,Z} = 0, in which case the covariance term in (17) is zero.
Now consider the case where the outcome model is negative binomial regression, and suppose the
conditional mean function is correctly specified. In this case the part of the estimating equations corre-
sponding to β have expectation conditional on X and Z equal to zero. It also follows (see [4]) that the
matrix M is block diagonal, and hence so is M−1. Then we have
E{Gθψ(Y,X,Z)|X,Z} = −
(
Gβ 0
)
M
−1
E
{
m(Y,X,Z, θ˜|X,Z)
}
= −
(
Gβ 0
)(m−111 0
0 m−122
)(
0
φ(X,Z)
)
= 0
Thus in this case again the covariance term in (17) is zero.
Suppose then that the covariance in equation (17) is zero. A key property of the influence function
ψ(Y,X,Z) is that θˆ = (βˆ, ηˆ) is asymptotically normally distributed with mean θ˜ = (β˜, η˜) and variance
n−1Var{ψ(Y,X,Z)}. Consequently,
Var{Gθψ(Y,X,Z)} = nGθVar(θˆ)G
T
θ
= n
(
Gβ 0
)
Var(θˆ)
(
GTβ
0
)
= nGβVar(βˆ)G
T
β
We then have that µˆ2(z) has variance
n
−1Var
{
h(X, z, β˜)− µ(z)
}
+GβVar(βˆ)G
T
β (19)
The second term in this expression corresponds to the variance estimator proposed by Qu and Luo [10].
As such, this expression shows that when the covariance term in (17) is zero, the variance estimator
proposed by Qu and Luo underestimates the variance of µˆ2(z) by n
−1Var
[
h(X, z, β˜)− µ(z)
]
. Although
this bias term tends to zero as n increases, it converges at the same rate as the other contribution to the
variance, such that the Qu and Luo variance estimator will be biased downwards even for large sample
sizes. Equation (19) implies that a valid variance estimate for µˆ2(z) can be obtained, assuming the
outcome model estimating function is conditionally unbiased, by adding
n
−2
n∑
i=1
{h(X, z, βˆ)− µˆ(z)}2
to the Qu and Luo variance estimator given in equation (7).
14
A.3 Efficiency compared to µˆ1(z)
In this section we give a sketch proof to show that µˆ2(z) is a more efficient estimator than µˆ1(z), when
the outcome model is a correctly specified parametric model estimated by maximum likelihood. Let
f(Y |X,Z, θ) denote this model, with E(Y |X,Z) = h(X,Z, θ). We assume a nonparametric model for
X, and P (Z = z|X) = piz by randomisation. We then use semiparametric theory as described in [14] to
demonstrate that µˆ2(z) is the most efficient estimator in this semiparametric model, and therefore that
it is more efficient than µˆ1(z).
To derive the efficient estimator, we find the tangent space. Thus consider a parametric submodel,
where f(X|λ) is a parametric model for X. Since no model is required for P (Z|X), the tangent space
for this (arbitrary) parametric submodel is Jθ ⊕ Jλ where
Jθ =
{
B
1×p
Sθ(Y,X, Z) : for all vectors B
1×p}
where Sθ(Y,X,Z) is the score vector corresponding to the parametric model f(Y |X,Z, θ), and
Jλ =
{
B
1×q
Sλ(X) : for all vectors B
1×q
}
where Sλ(X) is the score vector corresponding to the (arbitrary) parametric model for X. By definition,
the tangent space for the semiparametric model is the mean square closure of all parametric submodel
tangent spaces. Since θ and λ are variationally independent, the tangent space for the semiparametric
model is Jθ ⊕ J1 where
J1 = {g(X) : E(g(X)) = 0}
is the mean square closure of the submodel tangent spaces Jλ. The estimator µˆ1(z) clearly belongs to
the class of RAL estimators for this semiparametric model. The influence function for µˆ1(z) is
1(Z = z)
piz
{Y − µ(z)}
The influence function of µˆ2(z) is
h(X, z, θ)− µ(z) +Gθ{E(SθS
T
θ )}
−1
Sθ(Y,X,Z)
where
Gθ = E
[
∂h(X, z, θ)
∂θT
]
= E
[
∂E(Y |X, z, θ)
∂θT
]
We now show that µˆ2(z) is semiparametric efficient in this model. To show this, we show that the
projection of the influence function of µˆ1(z) onto the tangent space is equal to the influence function of
µˆ2. Since the tangent space is the direct sum of two orthogonal spaces, the projection is equal to the
sum of the projection onto Jθ and the projection onto J1. The projection onto J1 is equal to
E
[
1(Z=z)
piz
{Y − µ(z)} |X
]
= h(X, z, θ)− µ(z)
The projection onto Jθ is equal to
E
[
1(Z = z)
piz
{Y − µ(z)}STθ
]
{E(SθS
T
θ )}
−1
Sθ(Y,X,Z)
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Assuming that E(Sθ|X,Z) = 0, the first expectation in this projection can be expanded as
E
[
1(Z = z)
piz
{Y − µ(z)}STθ
]
= E(Y STθ |Z = z)
= E
[
E(Y STθ |X,Z = z)|Z = z
]
= E
[∫
Y S
T
θ f(Y |X, z)dY |Z = z
]
= E
[∫
Y
∂
∂θT
f(Y |X, z, θ)
f(Y |X, z, θ)
f(Y |X, z, θ)dY |Z = z
]
= E
[∫
Y
∂
∂θT
f(Y |X, z, θ)dY |Z = z
]
= E
[
∂
∂θT
E(Y |X, z, θ)
]
= Gθ
assuming sufficient regularity conditions in order to exchange differentiation and integration. We thus
conclude that µˆ2(z) is semiparametric efficient. Lastly, since µˆ2(z) is semiparametric efficient for this
model, it is in particular more efficient than µˆ1(z).
B Asymptotic theory for µˆ3(z)
B.1 Derivation of µˆ3(z)
To apply the results of Zhang et al [17], we first recall that the estimator µˆ1(z) which does not exploit
X can be expressed as solving estimating equations with estimating function 1(Z = z){Y − µ(z)}. For
this estimating function, application of their results then gives that all unbiased estimating functions for
µ(z) may be written as
1(Z = z){Y − µ(z)} −
k∑
g=1
{1(Z = g)− pig}ag(X)
where k is the number of treatment groups and ag(X) is an arbitrary one dimensional function of X.
The choice of ag(X) affects the efficiency of the resulting estimator of µ(z). The results of Zhang et al
show that the most efficient choice is
ag(X) = E{1(Z = z){Y − µ(z)}|X,Z = g)
which equals 0 for g 6= z and equals E(Y |X,Z = z) − µ(z) for g = z. Thus the efficient estimator has
estimating function
1(Z = z){Y − µ(z)} − {1(Z = z)− piz}{E(Y |X,Z = z)− µ(z)} (20)
Since E(Y |X,Z) is unknown, we may postulate and fit a parametric working model for it, h(X,Z, β),
and replace E(Y |X,Z) by h(X,Z, βˆ) in (20). The resulting estimator of µ(z) is locally efficient, in the
sense that if the working model is correctly specified, the estimator attains the semiparametric efficiency
bound. Even if it is not correctly specified, the estimator remains consistent.
In a randomised trial, the randomisation probabilities piz are known by design. Nonetheless, it turns
out (P206 of [14]) that in general a more efficient estimator can be obtained by replacing the known piz
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by their empirical estimates pˆiz, giving an estimating function
1(Z = z){Y − µ(z)} − {1(Z = z)− pˆiz}{E(Y |X,Z = z)− µ(z)}
Solving the resulting estimating equation leads to
µˆ3(z) = µˆ1(z)− n
−1
n∑
i=1
[
1(Zi = z)− pˆiz
pˆiz
h(Xi, z, βˆ)
]
The estimator pˆiz has estimating function 1(Z = z) − piz. As a so called two step estimator, it follows
from Theorem 6.1 of Newey [9] that µˆ3 has asymptotic variance
pi
−2
z E
[{
1(Z = z){Y − µ(z)} − {1(Z = z)− piz}{h(X, z, β˜)− µ(z)}+ {1(Z = z)− piz}{E(h(X, z, β˜))− µ(z)}
}2]
= pi−2z E
[{
1(Z = z){Y − µ(z)} − {1(Z = z)− piz}{h(X, z, β˜)− E(h(X, z, β˜))}
}2]
It follows that the variance of µˆ3(z) can be estimated by
pˆi
−2
z n
−2
n∑
i=1
[
1(Zi = z){Yi − µˆ3(z)} − {1(Zi = z)− pˆiz}{h(Xi, z, βˆ)− µˆ2(z)}
]2
Now consider the setting where Y denotes the number of events occurring for a patient, and T denotes
their follow-up time. The estimating function corresponding to µˆ1(z) is then 1(Z = z){Y −µ(z)T}. Here
T and Y are jointly considered as the outcome. Applying the results of Zhang et al [17], the efficient
estimating function is
1(Z = z){Y − µ(z)T} − {1(Z = z)− piz}{E(Y |X,Z = z)− µ(z)E(T |X,Z = z)}
The two conditional expectations involved are again unknown, but we can construct a feasible estimator
by postulating working models for them. To motivate our choices, we make the working assumption
that T ⊥⊥ X|Z, since if this did not hold, in general it would be the case that E(Y |T, Z) 6= µ(z)T , such
that µˆ1(z) would not be consistent. Under this conditional independence assumption, E(T |X,Z = z) =
E(T |Z = z), and this latter quantity can be estimated by the sample mean of T in those randomised
to Z = z, which we denote τˆz. For E(Y |X,Z = z) we approximate it by τˆzh(X, z, β), where h(X,Z, β)
denotes a working model prediction for E(Y |X,Z, T = 1). Again substituting pˆiz in place of piz, this
leads to
µˆ3(z) =
∑n
i=1 1(Zi = z)Yi − {1(Zi = z)− pˆiz}{h(Xi, z, βˆ)τˆz}∑n
i=1 1(Zi = z)Ti
= µˆ1(z)− n
−1
n∑
i=1
[
1(Zi = z)− pˆiz
pˆiz
h(Xi, z, βˆ)
]
Again using Theorem 6.1 of Newey [9], it follows after further algebra that the variance of µˆ3(z) can be
estimated by
pˆi
−2
z τˆ
−2
z n
−2
n∑
i=1
[
1(Zi = z){Yi − µˆ3(z)} − τˆz{1(Zi = z)− pˆiz}{h(Xi, z, βˆ)− µˆ2(z)}
]2
B.2 Canonical generalised linear models
We now show that for certain outcome model specifications, the estimator µˆ2(z) described in Section 3
actually corresponds to an estimator of the form of µˆ3(z), and as such, inherits the asymptotic properties
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of the latter. First, we re-express µˆ3(z) as
µˆ3(z) = n
−1
n∑
i=1
[
h(Xi, z, βˆ) +
1(Zi = z)
pˆiz
{
Yi − h(Xi, z, βˆ)
}]
Now suppose that the estimating equations used to estimate β include
n∑
i=1
1(Zi = z)
{
Yi − h(Xi, z, βˆ)
}
= 0 (21)
Then we have that µˆ3(z) = n
−1∑n
i=1 h(Xi, z, βˆ) = µˆ2(z). In this case, µˆ2(z) is consistent for µ(z),
without requiring the outcome model to be correctly specified in any respect. Moreover, the variance
estimator given in equation (11) can be used to estimate its variance, and this is valid even when the
outcome model used is misspecified.
An important collection of models satisfying the condition given in equation (21) are canonical link
generalised linear models (GLMs) which include an intercept and main effect of Z [4]. These include
logistic regression for binary outcomes and Poisson regression for count outcomes.
C Stratified randomisation
In this appendix we consider the impact of stratified randomisation on the variance of µˆ2(z), when the
covariates used in the stratified randomisation are included within the covariates X. Then a reasonable
assumption is that for i 6= j, Yi ⊥⊥ (Yj , Xj , Zj)|(Xi, Zi). That is, that conditional on a patient’s covariates
and treatment assignment, their outcome does not depend on the data from any other patients. The
covariance between the contributions to the estimating equation for β from any two patients is then
Cov [m(Yi, Xi, Zi, β),m(Yj , Xj , Zj , β)]
= Cov [E{m(Yi, Xi, Zi, β)|Xi, Zi}, E{m(Yj, Xj , Zj , β)|Xi, Zi}]
+ E [Cov{m(Yi, Xi, Zi, β),m(Yj , Xj , Zj , β)|Xi, Zi}]
If the outcome model is correctly specified, E{m(Yi, Xi, Zi, β)|Xi, Zi} = 0, and so the first covariance
term will be zero. The conditional covariance in the second term is zero due to the stated conditional
independence assumption. We have thus shown that under the stated conditions, the contributions to
the estimating function for β from distinct patients remain uncorrelated under stratified randomisation.
Conditional on β, µˆ2(z) only depends on the data through X, and since X remain i.i.d. under stratified
randomisation, the variance estimator derived previously for µˆ2(z) given in equation (19) remains valid
under stratified randomisation, under the stated conditions.
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